ValueScreener

ValueScreener company report

Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ / Healthcare / Biotechnology

Share price

9.85 USD Market dataClose of Oct 15, 2026

Market capitalisation

828.6M USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Mar 12, 2026
Ratios computed
Oct 15, 2026
Filed years
11, FY2014 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on invested capital, after tax

-74.7% Computed

From the FY2025 filing

Read quality

Valuation

Price to book

13.54x Computed

FY2025 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

-4.0% Computed

FY2025 accounts, priced at the latest close

Read cash generation

Revenue and net income, as filed

FY2016 Net income: -36.4M USDFY2017 Net income: -55.7M USDFY2018 Net income: -46.9M USDFY2019 Net income: -46.7M USDFY2020 Net income: -6.0M USDFY2021 Net income: -43.2M USDFY2022 Net income: -41.3M USDFY2023 Net income: -27.0M USDFY2024 Net income: -62.3M USDFY2025 Net income: -15.3M USD
Revenue Net income10 filed fiscal years, from the annual reports; the table in Filings names each document.
Named tests met
0 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it good

Return on invested capital was -74.7% in FY2025, in the band labelled "Likely below the cost of capital" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns below the usual cost of the capital employed.

Today, against the Biotechnology industry (78 companies), -74.7% sits at the 44th percentile; the middle half of that group runs from -124.0% to -4.0%.

Is it safe

Debt to equity was 0.02 in FY2025, in the band labelled "Conservative" (below 0.50), on lines anchored on Graham's defensive-investor criteria, suggesting a balance sheet that relies little on borrowing.

Today, against the Biotechnology industry (252 companies), 0.02 sits at the 34th percentile; the middle half of that group runs from 0.01 to 0.29.

Year by year against peers
Whether Corvus Pharmaceuticals, Inc.'s return on equity stayed above the median of the Biotechnology industry, year by year. (FY2021 to FY2025, 5 fiscal years of Corvus Pharmaceuticals, Inc. with a comparable figure)
The direction
Which way Corvus Pharmaceuticals, Inc.'s return on equity has moved, and how steadily. (FY2016 to FY2025, 10 filed years of Corvus Pharmaceuticals, Inc.)
What could explain it
What in Corvus Pharmaceuticals, Inc.'s filed statements could explain the movements. (4 readings drawn from the statement lines Corvus Pharmaceuticals, Inc. filed)
What to check next
What to check next on Corvus Pharmaceuticals, Inc., and where in its filings. (3 questions for Corvus Pharmaceuticals, Inc.)
In one paragraph
One paragraph on Corvus Pharmaceuticals, Inc.'s returns, cash, balance sheet and price. (6 of sixteen figures read for Corvus Pharmaceuticals, Inc.)

These are CRVS’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research CRVSPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 10-K, filed Mar 12, 2026, accession 0001104659-26-027047.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

Corvus Pharmaceuticals, Inc: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax-74.7% ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Return on equity-25.0% ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Return on capital employed, pre-tax-69.6% ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Return on assets-21.5% ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Gross margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Operating margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Net margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

Corvus Pharmaceuticals, Inc: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity0.02 ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Current ratio6.21 ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Quick ratio6.21 ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Interest coverage
Why n/a

No interest expense is filed for this year, so coverage is not computed.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Altman Z-score
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Net debt-55.9M ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Total assets 71.1MTotal liabilities 9.9MShareholders' equity 61.2MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What Corvus Pharmaceuticals, Inc owned and owed at the end of fiscal 2025, from the balance sheet it filed (10-K, filed Mar 12, 2026, 0001104659-26-027047).

Corvus Pharmaceuticals, Inc: balance sheet position
Total assets71.1M FiledFY2025 10-K, filed Mar 12, 2026
Total liabilities9.9M FiledFY2025 10-K, filed Mar 12, 2026
Shareholders' equity61.2M FiledFY2025 10-K, filed Mar 12, 2026
Cash56.8M FiledFY2025 10-K, filed Mar 12, 2026
Total debt937.0K FiledFY2025 10-K, filed Mar 12, 2026
Net debt-55.9M
Current ratio6.21
Debt to equity0.02
  • Interest cover: FY2025: No interest expense is filed for this year, so coverage is not computed.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

Corvus Pharmaceuticals, Inc: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
P/E on trailing twelve months23.57x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book13.54x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Price to sales
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Enterprise value to EBIT
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Enterprise value to EBITDA
Why n/m

EBITDA is zero or negative, so a multiple of it is not meaningful.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Diluted earnings per share-0.53 USD FiledFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047

We publish no fair value or price target of our own. Value CRVS on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for Corvus Pharmaceuticals, Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

Corvus Pharmaceuticals, Inc: valuation
Share price9.85 USD
Market capitalisation828.6M USD
Enterprise value to EBITDAn/m
Graham numbern/m
Diluted earnings per share, FY2025-0.53 USD

Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since Mar 10, 2017: low 4.09x, median 6.56x, high 74.57x, latest 23.57x. 296 trading days with a meaningful ratio, 2,116 more on a loss and left out. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.

Companies like Corvus Pharmaceuticals, Inc

  1. Kura Oncology, Inc. (KURA)Market cap 862.9M USD
  2. Monte Rosa Therapeutics, Inc. (GLUE)Market cap 863.4M USD
  3. Gyre Therapeutics, Inc. (GYRE)Market cap 678.6M USD
  4. Ginkgo Bioworks Holdings, Inc. (DNA)Market cap 791.9M USD
  5. Cybin Inc. Common Stock (HELP)Market cap 684.9M USD

Same industry (Biotechnology) and size band (Small, 300M to 2B), nearest in market value and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

Corvus Pharmaceuticals, Inc: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield-4.0% ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Free cash flow-33.0M USD ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Free cash flow margin
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
FY2016 Free cash flow: -30.1M USDFY2016 Net income: -36.4M USDFY2017 Free cash flow: -46.5M USDFY2017 Net income: -55.7M USDFY2018 Free cash flow: -41.3M USDFY2018 Net income: -46.9M USDFY2019 Free cash flow: -37.3M USDFY2019 Net income: -46.7M USDFY2020 Free cash flow: -34.9M USDFY2020 Net income: -6.0M USDFY2021 Free cash flow: -36.7M USDFY2021 Net income: -43.2M USDFY2022 Free cash flow: -27.3M USDFY2022 Net income: -41.3M USDFY2023 Free cash flow: -24.0M USDFY2023 Net income: -27.0M USDFY2024 Net income: -62.3M USDFY2025 Free cash flow: -33.0M USDFY2025 Net income: -15.3M USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

Corvus Pharmaceuticals, Inc.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
13.54xFY2025Oct 15, 2026
n/aFY2025Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
-4.0%FY2025Oct 15, 2026
-74.7%FY2025Mar 12, 2026
n/aFY2025Oct 15, 2026
n/a The only dividend lines on the filed cash flow statement are zeros the filer did not tag as the common dividend paid, so they say nothing about what reached the common holders.
0.02FY2025Mar 12, 2026
6.21FY2025Mar 12, 2026
n/aFY2025Oct 15, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/aFY2025Oct 15, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
n/aFY2025Mar 12, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
n/aFY2025Mar 12, 2026
n/a Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 11 filed fiscal years on record, FY2014 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 filed fiscal years, FY2016 to FY2025, read from the annual reports Corvus Pharmaceuticals, Inc filed with the SEC. Each year names its filing. Amounts in USD, as filed.

Corvus Pharmaceuticals, Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY2025n/a-43.0M-15.3M-0.53-33.0Mn/a-25.0%10-K, Mar 12, 20260001104659-26-027047
FY2024n/a-27.5M-62.3M-1.02n/an/a-191.3%10-K, Mar 25, 20250001558370-25-003621
FY2023n/a-23.4M-27.0M-0.56-24.0Mn/a-69.9%10-K, Mar 19, 20240001558370-24-003567
FY2022n/a-32.6M-41.3M-0.89-27.3Mn/a-73.6%10-K, Mar 28, 20230001558370-23-004792
FY2021n/a-38.6M-43.2M-1.03-36.7Mn/a-44.5%10-K, Mar 10, 20220001558370-22-003281
FY2020n/a-43.8M-6.0M-0.20-34.9Mn/a-8.3%10-K, Mar 25, 20210001558370-21-003462
FY2019n/a-48.9M-46.7M-1.59-37.3Mn/a-65.6%10-K, Mar 9, 20200001558370-20-002232
FY2018n/a-49.2M-46.9M-1.71-41.3Mn/a-42.5%10-K, Mar 7, 20190001558370-19-001660
FY2017n/a-56.5M-55.7M-2.72-46.5Mn/a-65.6%10-K, Mar 1, 20180001047469-18-001209
FY2016n/a-37.0M-36.4M-2.36-30.1Mn/a-27.4%10-K, Mar 10, 20170001047469-17-001459
  • Revenue: Fewer than two filed years carry revenue.
  • Earnings: Earnings was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Earnings per share was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Free cash flow: Free cash flow was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

Corvus Pharmaceuticals, Inc: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Piotroski F-score
Why n/a

Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.

n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001104659-26-027047
Named tests met0 of 30 Computed
Beta0.96 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 0 met, 19 not met, 11 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
None of the named tests.
Does not
Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); High returns and growth; High yield, low payout; Dividends and buybacks; Low beta, profitable; ROIC at or above WACC; Near the 52-week low; High returns, low debt; Owner earnings yield; High return on tangibles; Book or below, low debt (Walter Schloss); Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC; Cheapest quarter on P/B (David Dreman)
Not measured
Three forensic scores; Low PEG, low debt (Peter Lynch); Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); P/E times P/B (Benjamin Graham); Low P/S, rising earnings (James O'Shaughnessy); Cash-covered dividend; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(19)
  • Piotroski F-Score: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
  • Altman Z-Score: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Beneish M-Score: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • Rev Growth 5Y: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Gross Margin: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Asset Turnover: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • EV/EBITDA: EBITDA is zero or negative, so a multiple of it is not meaningful.
  • Interest Coverage: No interest expense is filed for this year, so coverage is not computed.
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Price To Ncav: The filed share count failed its unit check, so there is no market value we can show you the inputs of.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • P/S Ratio: Our archived income statement for this filer carries no revenue line. A development-stage company files exactly that, with no revenue to report. Either way there is no denominator, and a ratio measured against a missing denominator is not zero, it is nothing.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 19 figures could not be read on this company, among them Piotroski F-Score, P/E Ratio, EV/EBIT. Each blank in the table above names the rest, with its reason. 11 named tests come back incomplete because of them, which is neither met nor missed.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy